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 Abstract 
 Aim: The aim of this study was to compare the perfor-
mance of tests based on the detection of insulin-like 
growth factor binding protein 1 (IGFBP-1) and placental 
 α -microglobulin-1 (PAMG-1) in diagnosing rupture of fetal 
membranes (ROM) across different patient populations. 
 Methods: A meta-analysis was conducted on prospective 
observational or cohort studies investigating ROM tests 
based on the detection of IGFBP-1 and PAMG-1 meeting the 
following criteria: (1) performance metrics calculated by 
comparing results to an adequate reference method; (2) 
sensitivity thresholds of the investigated tests matching 
those of the currently available tests; (3) study population, 
as a minimum, included patients between 25 and 37 weeks 
of gestation. Sensitivities, specificities, and diagnostic 
odds ratios were calculated. 
 Results: Across all patient populations, the analyzed perfor-
mance measures of the PAMG-1 test were significantly supe-
rior compared with those of the IGFBP-1 test. Of particular 
clinical relevance, PAMG-1 outperformed IGFBP-1 in the 
equivocal group, which comprised patients with uncertain 
rupture of membranes (sensitivity, 96.0 % vs. 73.9 % ; specific-
ity, 98.9 % vs. 77.8 % ; PAMG-1 vs. IGFBP-1 tests, respectively). 
 Conclusions: Compared with its performance in women 
with known membrane status, the accuracy of the IGFBP-1 
test decreases significantly when used on patients whose 
membrane status is unknown. In this latter clinically rele-
vant population, the PAMG-1 test has higher accuracy than 
the IGFBP-1 test. 
 Keywords:  Clinical relevance;  insulin-like growth factor 
binding protein (IGFBP-1);  placental  α -microglobulin 1 
(PAMG-1);  premature rupture of fetal membranes (PROM); 
 uncertain rupture. 
 *Corresponding author: Babett Ramsauer , MD, Vivantes Hospital 
Neukölln, Babett Ramsauer, Perinatal Medicine, Rudowerstr. 48, 
D-12351 Berlin, Germany, Tel.: +49 30130148486, 
Fax: +49 30130148599, E-mail:  ramsauer.publication@gmail.com 
 Alex C.  Vidaeff:  Baylor College of Medicine ,  Houston, TX ,  USA 
 Irene  H ö sli:  University Hospital Basel ,  University of Basel, Basel , 
 Switzerland 
 Joong Shin  Park:  College of Medicine ,  Seoul National University, 
Seoul ,  Korea 
 Alexander  Strauss:  University Hospital of Schleswig-Holstein ,  Germany 
 Zulfiya  Khodjaeva:  Federal Research Center for Obstetrics and 
Gynecology and Perinatology ,  Moscow ,  Russia 
 Á ngel Aguar ó n  de la Cruz:  Hospital General Universitario Gregorio 
Mara ñ ó n ,  Complutense University of Madrid, Madrid ,  Spain 
 Txant ó n  Mart í nez-Astorquiza:  Cruces University Hospital ,  University 
of the Basque Country, Bilbao ,  Spain 
 Jacques  Horovitz and  Frederic  Coatleven:  University of Bordeaux , 
 Bordeaux ,  France 
 Hanns  Helmer:  Medical University of Vienna ,  Vienna,  Austria 
 Introduction 
 Over the years, more than 100 different approaches have 
been proposed in obstetrical practice for the diagnosis 
of premature or prelabor rupture of the fetal membranes 
(PROM)  [13, 45] . The mere number of such attempts signals 
the importance of making an accurate diagnosis of PROM. 
PROM is encountered in 10 % of all pregnancies, with up to 
5 % of those cases occurring preterm [referred to as preterm 
PROM (PPROM)]. The latter group accounts for up to 40 % 
of all spontaneous preterm births  [3, 20] . It follows that 
an accurate diagnosis of PROM is essential in guiding the 
clinical management and allowing for the early and timely 
administration of antibiotics, corticosteroids, and other 
interventions to help reduce the effects of prematurity  [35] . 
 Despite the high number of proposed methods for the 
diagnosis of PROM, most have not entered into or persisted 
in routine clinical practice. Some were just impractical, 
whereas others performed poorly in unknown cases (mem-
brane status unknown at the time of presentation with sus-
picion of ROM), despite good performance previously dem-
onstrated in known samples or unequivocal cases. 
 A good example of a test that is impractical for routine 
use is the intra-amniotic injection of indigo carmine dye; 
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consequently, its use remains very limited  [4] . Well-known 
examples of methods with poor performance in unknown 
cases and whose role was limited to that of a supportive 
test rather than a confirmatory one are the fern test  [10, 
48] and the fetal fibronectin (fFN) test  [15, 22] . 
 The more recent literature has focused prevalently 
on two ROM biomarker tests: the AmniSure  ®  ROM Test 
(AmniSure  ®  lnternational LLC, Boston, MA, USA), based 
on the detection of placental  α -microglobulin 1 ( PAMG-
1), and the Actim  ®  Prom Test (Oy Medix Biochemica Ab, 
Kauniainen, Finland), based on the detection of insulin-
like growth factor binding protein (IGFBP-1)  [12, 25, 27, 
39] . The test based on PAMG-1 is the more recent of the 
two, with the first study on it being published in 2005, vs. 
1996 for the test based on IGFBP-1  [8, 41] . The objective of 
this systematic review was to compare the performance 
of these two tests in relevant patient populations. 
 Methods 
 Data source 
 The literature published in any language between 1990 and 2011 
was searched for papers on the diagnosis of premature or prelabor 
rupture of the fetal membranes. We searched the MEDLINE biblio-
graphic database using a combination of keywords, including  “ rup-
ture of membranes ” ,  “ insulin-like growth factor binding protein ” , 
 “ IGFBP-1 ” ,  “ placental  α -microglobulin 1 ” , and  “ PAMG-1 ” . All refer-
ences in the retrieved articles were screened for further papers. Edi-
torials, proceedings of meetings, and reviews, although not included 
in the analysis, were scanned for relevant studies not quoted by the 
database. 
 Study selection 
 Only prospective observational or cohort studies that met the fol-
lowing criteria were included in the meta-analysis: (1) the perfor-
mance metrics were calculated by comparing the results with an 
adequate reference method for the diagnosis of ROM as defined 
later; (2) the investigated test(s) had sensitivity thresholds match-
ing those of the currently available tests for the respective anti-
gens: 5 ng/mL  in vivo for PAMG-1  [8] and 400 ng/mL  in vivo for 
IGFBP-1 (i.e., 25 ng/mL  in vitro )  [41] ; and (3) the study population 
included (but was not confined to) patients between 25 and 37 
weeks of gestation. 
 An adequate reference method is one that is expected to be 
accurate, such as (a) visible leakage from the cervical os or intra-
amniotic injection of indigo carmine dye or (b) a chart review of the 
patient ’ s clinical course from initial diagnosis that includes outcome 
measures closely linked to the clinical pathology of ROM (e.g., du-
ration of latency period, time to delivery, results of repeat examina-
tions, signs of fetal distress, chorioamnionitis)  [45] . On the contrary, 
an inadequate reference method is one with limited accuracy, such 
as the diamine oxidase (DAO) or fFN test. 
 To establish clinical homogeneity among patient populations 
from the included studies, two main groups were created to compare 
performance metrics: 
1.  Known group: cases with unequivocally ruptured membranes 
(e.g., artificially ruptured membranes, gross leakage of 
amniotic fluid, or known amniotic fluid samples used in 
the study) or unequivocally not ruptured membranes (e.g., 
asymptomatic women presenting for routine antenatal 
screening without complaints of leakage). 
2.  Unknown group: patients presenting with signs and symptoms 
of ROM with unknown membrane status at the time of study 
enrollment. 
 One study may appear in more than one patient population group 
when more than one set of performance metrics relevant to diff erent 
patient populations were used in the study. 
 From each study, the following data were extracted: the total 
number of patients and the number of true-positive, true-negative, 
false-positive, and false-negative results for the diagnosis of ROM. 
The performance measures for the PAMG-1 and IGFBP-1 tests were 
sensitivity, specifi city, and the diagnostic odds ratios. Sensitivity and 
specifi city tests assessed diagnostic accuracy without being infl u-
enced by the diff erent prevalence of ROM within the diff erent patient 
population groups, and the diagnostic odds ratio is one of the better 
measures of overall accuracy, as it makes the most effi  cient use of 
all data points. The performance of the same test in diff erent patient 
populations was compared as well as the performance of the two 
tests in the same patient population. 
 Weighted least squares regressions on the logits of each meas-
ure were performed, with the weights inversely proportional to the 
variance of the logits. Signifi cance was determined at the 0.05 level 
through  t -tests on the coeffi  cients. In cases where a false-negative or 
false-positive value was 0, 0.5 was added to that value, whereas 0.5 
was subtracted from the true-positive or negative-value, depending 
on the measure being calculated  [17] . 
 Results 
 Study selection 
 The search yielded 36 articles, eight of which related spe-
cifically to the PAMG-1 test  [5, 8, 29 – 31, 36, 37, 43] , 24 to the 
IGFBP-1 test  [1, 6, 9, 11, 14, 16, 18, 19, 21, 23, 24, 26 – 28, 32 –
 34, 38, 40, 42, 46, 47, 49, 50] , and seven that were related to 
both  [2, 7, 13, 25, 39, 44, 45] . The supplementary search of 
proceedings of perinatal meetings yielded three abstracts, 
all of which related specifically to the PAMG-1 test  [31, 36, 
43] . Together, 39 studies were identified and evaluated 
further for inclusion into the meta-analysis. Figure  1 illus-
trates the study selection algorithm. 
 The first filter isolated 21 prospective observational 
studies that investigated one or both of the biomarkers 
for their ability to diagnose ROM. The 18 studies that were 
excluded were review articles, investigated a property of 
the testing device itself (e.g., reproducibility of testing 
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results), or investigated the ability of the test for an alter-
native indication (e.g., prediction of preterm delivery). 
 The second filter isolated 14 of the 21 remaining studies 
based on the inclusion criterion stipulating that the tests 
detection thresholds should match those of the commer-
cially available tests for the respective antigens. The 7 
studies that were eliminated were specifically related to 
the detection of IGFBP-1 and did not match the detection 
threshold of the commercially available kit (400 ng/mL 
 in vivo ; 25 ng/mL  in vitro ). All of the 14 selected studies 
included patients between 25 and 37 weeks of gestation, 
satisfying all the inclusion criteria. 
 Finally, 2 more studies were eliminated from further 
evaluation on account of an inadequate reference method 
to generate performance metrics. In one study  [1] , the 
IGFBP-1 test was compared with the results of DAO, a 
method that is not considered accurate in diagnosing ROM 
 [45] , and in the other  [21] , the performance metrics for 
PAMG-1: Placental alpha microglobulin-1 test specific study(s)
IGFBP-1: Insulin-like growth factor binding protein-1 test specific study(s)
Both: PAMG-1 and IGFBP-1 tests included in the study(s)
MEDLINE 
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Manual Abstract Search (2006–2011)
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No 
Yes
12 studies included
(4) Was an adequate reference method used
      from which performance metrics of the test
      investigated were generated?
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(1) Is the study prospective observational
      investigating a biomarker test for its ability
      to diagnose rupture of membranes?
No 
Yes
PAMG-1
(3) Does the gestational age of the patient
      population include weeks 25 through 37 of
      gestation?
No 
Yes
0
PAMG-1  0
IGFBP-1  [1, 21] 2
Both  0
ARTICLES n=36
ABSTRACTS n=3
PAMG-1 8
IGFBP-1 24 
Both 7
PAMG-1 [5, 8, 30, 43]  4
IGFBP-1 [9, 14, 24, 26, 34, 41]  6
Both        [2, 44]   2
PAMG-1 [29, 31, 36, 37]   4
IGFBP-1 [6, 11, 16, 19, 28, 33, 38, 46, 47]  9
Both        [7, 13, 25, 39, 45]   5
IGFBP-1  [18, 23, 32, 40, 42, 49, 50]    7
Both              0
PAMG-1  0
IGFBP-1  0
Both  0
PAMG-1  [5, 8, 30, 43]   4
IGFBP-1  [1, 9, 14, 21, 24, 26, 34, 41]  8
Both         [2, 44]    2
PAMG-1  [5, 8, 30, 43]  4
IGFBP-1  [1, 9, 14, 21, 24, 26, 34, 41] 8
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PAMG-1  [5, 8, 30, 43]    4
IGFBP-1  [1, 9, 14, 18, 21, 23, 24, 15
                 26, 32, 34, 40–42, 49, 50]
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 Figure 1   Study selection process. PAMG-1 = placental  α -microglobulin-1 test specific study(s), IGFBP-1 = insulin-like growth factor binding 
protein-1 test specific study(s), both = PAMG-1 and IGFBP-1 tests included in the study(s). 
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the IGFBP-1 test were based on a heterogeneous outcome 
measure (delivery within 2 weeks) that does not allow for 
a direct association with ROM. It is noted that this study 
could have been eliminated from further evaluation during 
the second filter instead of the third because although the 
IGFBP-1 test used had a detection threshold matching that 
of the commercially available kit for IGFBP-1, the test was 
performed by placing the testing strip directly into the cer-
vical os and posterior fornix of the vagina without the use 
of the collection swab  [1] . Given that Rutanen et al.  [41] 
highlighted that the swab is responsible for a 1:16 dilution 
of the sample, the use of the test without the swab lowers 
the detection threshold of the test quite substantially. 
 Grouping performance metrics by patient 
population group 
 Table  1 outlines the grouping of the various performance 
metrics by the patient population group from which they 
were derived. From the included 12 studies, 16 sets of perfor-
mance metrics were extracted. Six of these sets were for the 
PAMG-1 test (unknown group) and 10 were for the IGFBP-1 
test (known and unknown group). No sets of performance 
metrics were identified for the PAMG-1 test in patients that 
had unequivocally ruptured membranes or unequivo-
cally not ruptured membranes (i.e., the known group). For 
both the PAMG-1 and IGFBP-1 test, six sets of performance 
metrics were identified that were derived from patients pre-
senting with suspected ROM but with unknown membrane 
status at the time of presentation (i.e., the unknown group). 
 Comparison of performance metrics between 
tests and within patient population groups 
 Across all patient population groups (known and 
unknown), the PAMG-1 test performed significantly better 
than the IGFBP-1 test with respect to all performance 
measures (P < 0.01; Table  2 ). 
 For the unknown group specifically, the PAMG-1 
test performed significantly better than the IGFBP-1 test, 
with respect to all performance measures (P < 0.012; 
Table 2). Figure  2 illustrates how each test performed in 
the unknown group using the averages of the measures 
GA range Study PPG TP FN TN FP n SN ( % ) SP ( % ) DOR a 
PAMG-1 test
   24 – 42 Silva et al.  [43] b Unknown 21 0 42 0 63 100 100 3403
   17 – 42 Birkenmaier et al.  [5] b Unknown 51 3 143 2 199 94.4 98.6 1216
   15 – 42 Cousins et al.  [8] Unknown 90 1 112 0 203 98.9 100 20,048
   11 – 42 Lee et al.  [30] Unknown 157 2 21 3 183 98.7 87.5 550
   17 – 37 Tagore and Kwek  [44] Unknown 38 3 59 0 100 92.7 100 1475
   16 – 41 Albayrak et al.  [2] Unknown 83 5 77 2 167 94.3 97.5 639
 Average c Unknown 440 14 454 7 915 96.9 98.5 2038
IGFBP-1 test
   25 – 42 Darj and Lyren ä s  [9] b Unknown 46 19 30 4 99 70.8 88.2 18
   22 – 42 Jeurgens-Borst et al.  [24] b Unknown 22 5 40 16 83 81.5 71.4 11
   24 – 39 Martinez et al.  [34] Unknown 19 3 20 7 49 86.4 74.1 18
   16 – 41 Albayrak et al.  [2] Unknown 79 9 77 2 167 89.8 97.5 338
   15 – 41 Kubota and Takeuchi  [26] Unknown 18 1 27 2 48 94.7 93.1 243
   17 – 37 Tagore and Kwek  [44] Unknown 35 5 51 3 94 87.5 94.4 119
 Subaverage b Unknown 219 42 245 34 540 83.9 87.8 38
   20 – 42 Erdemoglu and Mungan  [14] Known 35 1 34 1 71 97.2 97.1 1190
   15 – 41 Kubota and Takeuchi  [26] Known 40 2 38 4 84 95.2 90.5 190
   24 – 39 Martinez et al.  [34] Known 20 0 13 1 34 100 92.9 500
   15 – 37 Rutanen et al.  [41] Known 55 0 71 4 130 100 94.7 1939
 Subaverage c Known 150 3 156 10 319 98.0 94.0 780
 Average c 369 45 401 44 859 89.1 90.1 75
 Table 1   Performance measures by patient population group. 
 GA = gestational age, PPG = patient population group, TP = true-positive, FN = false-negative, TN = true-negative, FP = false-positive, n = total 
number, SN = sensitivity, SP = specificity, DOR = diagnostic odds ratio.  a A value of 0.5 was added to an FN or FP of 0, and 0.5 was subtracted 
from the true-positive or true-negative value depending on the measure being calculated.  b Patient population consisted of only those 
presenting with suspicion of ROM who did not have gross or obvious ruptures, i.e., the equivocal group.  c Averages were calculated for each 
diagnostic measure using the pooled TP, FN, TN, and FP numbers from the studies within the specified group. 
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(sensitivity, 96.9 % vs. 83.9 % ; specificity, 98.5 % vs. 87.8 % ; 
PAMG-1 test and IGFBP-1 test, respectively). 
 The IGFBP-1 test performed significantly better in the 
known group than in the unknown group with respect 
to sensitivity (P = 0.008; Table  3 ) and the diagnostic odds 
ratio (P = 0.017; Table 3). Figure  3 illustrates how the 
IGFBP-1 test performed in both patient population groups 
using averages of the measures (sensitivity, 98.0 % vs. 
83.9 % ; specificity, 94.0 % vs. 87.8 % ; known and unknown 
IGFBP-1 groups, respectively). Because no studies were 
found investigating the performance of the PAMG-1 test in 
known samples or unequivocal patient cases, it was not 
possible to compare the performance of this test between 
the groups. 
 A subgroup analysis was also performed on the per-
formance of each test in patients presenting with sus-
pected ROM but for whom leakage from the cervical os 
could not be visualized. We called this subgroup of the 
unknown group, the  “ equivocal group ” . For the equivocal 
Description Performance measure Interpretation of statistically significant results a 
SN SP DOR
PAMG-1 vs. IGFBP-1: unknown and known 0.009 a 0.005 a 0.001 a The PAMG-1 test performed better than the IGFBP-1 test overall.
PAMG-1 vs. IGFBP-1: unknown 0.005 a 0.011 a 0.003 a The PAMG-1 test performed better than the IGFBP-1 test in the 
unknown group.
 Table 2   Test comparison within and between patient population groups statistical analysis. 
 SN = sensitivity, SP = specificity, DOR = diagnostic odds ratio.  a Significance level, P < 0.05. 
100% 96.9%
83.9%
SN SP
PAMG-1
IGFBP-1
98.5%
87.8%
95%
90%
85%
80%
75%
70%
65%
60%
 Figure 2   PAMG-1 vs. IGFBP-1 in the unknown group using averages 
of the measures. 
Description Performance measure Interpretation of statistically significant results a 
SN SP DOR
IGFBP-1: unknown vs. known 0.008 a 0.504 0.017 a The IGFBP-1 test performed better in the known group than in the unknown group.
PAMG-1: unknown vs. known N/A N/A N/A Not applicable because the known group does not exist for the PAMG-1 test.
 Table 3   Individual test performance between patient population group statistical analyses. 
 SN = sensitivity, SP = specificity, DOR = diagnostic odds ratio.  a Significance level, P < 0.05. 
group, the PAMG-1 test performed significantly better than 
the IGFBP-1 test with respect to the diagnostic odds ratio 
(P = 0.019; Table  4 ). Figure  4 illustrates how each test per-
formed in the equivocal group using averages of the meas-
ures (sensitivity, 96.0 % vs. 73.9 % ; specificity, 98.9 % vs. 
77.8 % ; PAMG-1 test and IGFBP-1 test, respectively). 
 Lastly, the IGFBP-1 test performed significantly better 
for the known group than it did for the equivocal group 
with respect to sensitivity (P = 0.042; Table 4) and the 
diagnostic odds ratio (P = 0.018; Table 4). Figure  5 illus-
trates how the IGFBP-1 test performed in the known and 
equivocal patient population groups using averages of 
the measures (sensitivity, 98.0 % vs. 73.9 % ; specificity, 
94.0 % vs. 77.8 % ; known and equivocal IGFBP-1 groups, 
respectively). Because no studies were found investigat-
ing the performance of the PAMG-1 test in known samples 
or obvious patient cases, we were unable to compare the 
performance of this test for the equivocal group to that for 
the known group. 
 Discussion 
 Although it was found that all studies investigating the 
PAMG-1 test were conducted solely on patients with 
unknown membrane status, many of studies specifically 
focusing on the IGFBP-1 test included a patient popula-
tion for whom there existed no question about the status 
of their membranes (i.e., the known group)  [18, 21, 32, 36] . 
When the known and unknown groups were compared, 
we found that the sensitivity and diagnostic odds ratio 
for the IGFBP-1 test were lower in patients with unknown 
membrane status compared with those whose membrane 
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status was known. This finding has practical implications 
because in obstetrical care, the only clinically relevant 
population to test is that of women for whom the status of 
the membranes is not obvious at the time of presentation 
 [9, 28] . 
 Similarly, the classical fern test was found by de Haan 
et al.  [10] to perform better in obvious or known cases 
than in non-laboring patients suspected of ROM but with 
unknown membrane status. Coupled with the practi-
cal difficulties of maintaining microscopes and prepar-
ing samples, the poorer performance of the fern test in 
clinically relevant patient populations led to its eventual 
disuse in most European countries  [5] . 
 For the group of patients that were suspected to have 
had ROM but whose membrane status was unknown at 
the time of inclusion into the study (i.e., the unknown 
group), the PAMG-1 test performed significantly better 
than the IGFBP-1 test with respect to sensitivity, specific-
ity, and the diagnostics odds ratio (Table 2). 
 The PAMG-1 test was also compared with the IGFBP-1 
test with respect to their performance in the equivocal 
group (i.e., patients presenting with suspected ROM but 
for whom leakage from the cervical os could not be visu-
alized). As Figure 4 shows, the PAMG-1 test performed 
better than the IGFBP-1 test in the equivocal group across 
sensitivity and specificity measures (sensitivity, 96.0 % vs. 
73.9 % ; specificity, 98.9 % vs. 77.8 % ; PAMG-1 and IGFBP-1 
tests, respectively) and also in the diagnostic odds ratio 
100% 98.0%
83.9%
SN SP
IGFBP-1: Unknown
IGFBP-1: Known94.0%
87.8%
95%
90%
85%
80%
75%
70%
65%
60%
 Figure 3   Known group vs. unknown group for the IGFBP-1 test 
using averages of the measures. 
100%
98.9%
73.9%
77.8%
96.0%
SN SP
IGFBP-1
PAMG-1
95%
90%
85%
80%
75%
70%
65%
60%
 Figure 4   PAMG-1 vs. IGFBP-1 in the equivocal group using averages 
of the measures. 
100%
SN SP
95%
90%
85%
80%
75%
70%
65%
60%
IGFBP-1: Unknown
IGFBP-1: Known98.0%
73.9%
94.0%
77.8%
 Figure 5   Known group vs. equivocal group for the IGFBP-1 test 
using averages of the measures. 
Description Performance measure Interpretation of statistically significant results a 
SN SP DOR
PAMG-1 vs. IGFBP-1: equivocal 0.073 0.071 0.019 a The PAMG-1 test performed better than the IGFBP-1 test in the equivocal group.
IGFBP-1: equivocal vs. known 0.042 a 0.214 0.018 a The IGFBP-1 test performed better in the known group than in equivocal group.
 Table 4   Equivocal subgroup statistical analysis. 
 SN = sensitivity, SP = specificity, DOR = diagnostic odds ratio.  a Significance level, P < 0.05. 
(P = 0.019).  In vitro studies attempting to simulate the clini-
cally relevant patient cases in which membrane rupture 
is not obvious have demonstrated that the PAMG-1 test 
will remain positive for several serial dilutions of amniotic 
fluid beyond the level at which the IGFBP-1 test first reads 
negative  [7, 39] . The disparate  in vivo sensitivities of the 
two tests found in the present study in patients for whom 
membrane rupture is suspected, but not obvious, agree 
with the findings of the  in vitro simulations of this same 
patient group. 
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 Conclusion 
 Compared with its performance in women for whom mem-
brane status is known, the performance of the IGFBP-1 test 
decreases significantly when used on patients for whom 
membrane status is unknown. In this latter clinically rele-
vant population, the PAMG-1 test has higher accuracy than 
the IGFBP-1 test. 
 Received October 19, 2012. Accepted November 16, 2012. Previously 
published online December 25, 2012. 
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